BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yashiro M, Nishii T, Hasegawa T, Matsuzaki T, Morisaki T, Fukuoka T, Hirakawa K. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br J Cancer. 2013;109:2619-2628. [PMID: 24129235 DOI: 10.1038/bjc.2013.638] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Inokuchi M, Otsuki S, Fujimori Y, Sato Y, Nakagawa M, Kojima K. Clinical significance of MET in gastric cancer. World J Gastrointest Oncol 2015; 7(11): 317-327 [PMID: 26600931 DOI: 10.4251/wjgo.v7.i11.317] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
2 Vasconcelos AC, Wagner VP, Meurer L, Vargas PA, de Souza LB, Fonseca FP, Squarize CH, Castilho RM, Martins MD. Immunoprofile of c-MET/PI3K signaling in human salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol 2015;120:238-47. [PMID: 26117810 DOI: 10.1016/j.oooo.2015.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Jiang X, Feng K, Zhang Y, Li Z, Zhou F, Dou H, Wang T. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget 2015;6:12340-56. [PMID: 25895026 DOI: 10.18632/oncotarget.3656] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
4 Wood GE, Hockings H, Hilton DM, Kermorgant S. The role of MET in chemotherapy resistance. Oncogene 2021;40:1927-41. [PMID: 33526881 DOI: 10.1038/s41388-020-01577-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Matsuoka T, Yashiro M. The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel). 2014;6:1441-1463. [PMID: 25003395 DOI: 10.3390/cancers6031441] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 12.0] [Reference Citation Analysis]
6 Mezquita B, Pineda E, Mezquita J, Mezquita P, Pau M, Codony-servat J, Martínez-balibrea E, Mora C, Maurel J, Mezquita C. LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET: CHEMOTHERAPY RESISTANT COLON CANCER CELLS. Mol Carcinog 2016;55:411-9. [DOI: 10.1002/mc.22289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
7 Noble M, Mayer-Pröschel M, Li Z, Dong T, Cui W, Pröschel C, Ambeskovic I, Dietrich J, Han R, Yang YM, Folts C, Stripay J, Chen HY, Stevens BM. Redox biology in normal cells and cancer: restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment. Free Radic Biol Med 2015;79:300-23. [PMID: 25481740 DOI: 10.1016/j.freeradbiomed.2014.10.860] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
8 Van Der Steen N, Pauwels P, Gil-Bazo I, Castañon E, Raez L, Cappuzzo F, Rolfo C. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers (Basel) 2015;7:556-73. [PMID: 25815459 DOI: 10.3390/cancers7020556] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
9 Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol 2018; 24(26): 2818-2832 [PMID: 30018477 DOI: 10.3748/wjg.v24.i26.2818] [Cited by in CrossRef: 103] [Cited by in F6Publishing: 93] [Article Influence: 25.8] [Reference Citation Analysis]
10 Chen S, Wang Y, Chen L, Xia Y, Cui J, Wang W, Jiang X, Wang J, Zhu Y, Sun S, Zou Y, Gong Y, Shi B. CUL4B promotes aggressive phenotypes of renal cell carcinoma via upregulating c-Met expression. Int J Biochem Cell Biol 2021;130:105887. [PMID: 33227394 DOI: 10.1016/j.biocel.2020.105887] [Reference Citation Analysis]
11 Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol 2016; 22(20): 4812-4823 [PMID: 27239108 DOI: 10.3748/wjg.v22.i20.4812] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
12 Podolski-renić A, Milošević Z, Dinić J, Stanković T, Banković J, Pešić M. Mutual regulation and targeting of multidrug resistance and cancer stem phenotype. Med Chem Commun 2016;7:2265-81. [DOI: 10.1039/c6md00391e] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Muckenhuber A, Babitzki G, Thomas M, Hölzlwimmer G, Zajac M, Jesinghaus M, Bergmann F, Werner J, Stenzinger A, Weichert W. Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies: Looking at the Soil Before Planting the Seed. Pancreas 2016;45:1167-74. [DOI: 10.1097/mpa.0000000000000604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z, Wang L. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci 2015;16:6677-93. [PMID: 25811929 DOI: 10.3390/ijms16046677] [Cited by in Crossref: 105] [Cited by in F6Publishing: 107] [Article Influence: 15.0] [Reference Citation Analysis]
15 Jung KA, Choi BH, Kwak MK. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol. 2015;87:465-476. [PMID: 25534417 DOI: 10.1124/mol.114.096065] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
16 Cojoc M, Mäbert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Seminars in Cancer Biology 2015;31:16-27. [DOI: 10.1016/j.semcancer.2014.06.004] [Cited by in Crossref: 209] [Cited by in F6Publishing: 210] [Article Influence: 29.9] [Reference Citation Analysis]
17 Yang J, Yang L, Li S, Hu N. HGF/c-Met Promote Renal Carcinoma Cancer Stem Cells Enrichment Through Upregulation of Cir-CCDC66. Technol Cancer Res Treat 2020;19:1533033819901114. [PMID: 31994979 DOI: 10.1177/1533033819901114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Kim S, Barzi A, Rajdev L. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. Semin Oncol. 2018;45:133-150. [PMID: 30262395 DOI: 10.1053/j.seminoncol.2018.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Zhao L, Ren Y, Tang H, Wang W, He Q, Sun J, Zhou X, Wang A. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential. Oncotarget 2015;6:44538-50. [PMID: 26517090 DOI: 10.18632/oncotarget.6253] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
20 Zhang H, Feng Q, Chen WD, Wang YD. HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers. Int J Mol Sci 2018;19:E3295. [PMID: 30360560 DOI: 10.3390/ijms19113295] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
21 Erdem ZN, Schwarz S, Drev D, Heinzle C, Reti A, Heffeter P, Hudec X, Holzmann K, Grasl-Kraupp B, Berger W, Grusch M, Marian B. Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis. Transl Oncol 2017;10:332-9. [PMID: 28340475 DOI: 10.1016/j.tranon.2017.02.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
22 Matsuoka T, Yashiro M. Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases 2015; 3(1): 42-51 [PMID: 25610849 DOI: 10.12998/wjcc.v3.i1.42] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
23 Shao Q, Xu J, Guan X, Zhou B, Wei W, Deng R, Li D, Xu X, Zhu H. In vitro and in vivo effects of miRNA-19b/20a/92a on gastric cancer stem cells and the related mechanism. Int J Med Sci 2018;15:86-94. [PMID: 29333091 DOI: 10.7150/ijms.21164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
24 Abdel-Rahman O. Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. Expert Rev Anticancer Ther. 2015;15:235-245. [PMID: 25353620 DOI: 10.1586/14737140.2014.974564] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
25 Hsieh HL, Yu MC, Cheng LC, Yeh TS, Tsai MM. Molecular mechanism of therapeutic approaches for human gastric cancer stem cells. World J Stem Cells 2022; 14(1): 76-91 [DOI: 10.4252/wjsc.v14.i1.76] [Reference Citation Analysis]
26 Moosavi F, Giovannetti E, Peters GJ, Firuzi O. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Crit Rev Oncol Hematol 2021;160:103234. [PMID: 33497758 DOI: 10.1016/j.critrevonc.2021.103234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Jo JH, Kim SA, Lee JH, Park YR, Kim C, Park SB, Jung DE, Lee HS, Chung MJ, Song SY. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:1241. [PMID: 34794402 DOI: 10.1186/s12885-021-08898-y] [Reference Citation Analysis]
28 Kim HJ, Yoon A, Ryu JY, Cho YJ, Choi JJ, Song SY, Bang H, Lee JS, Cho WC, Choi CH, Lee JW, Kim BG, Bae DS. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. Sci Rep 2016;6:38502. [PMID: 27917934 DOI: 10.1038/srep38502] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
29 Song Y, Wang Y, Tong C, Xi H, Zhao X, Wang Y, Chen L. A unified model of the hierarchical and stochastic theories of gastric cancer. Br J Cancer 2017;116:973-89. [PMID: 28301871 DOI: 10.1038/bjc.2017.54] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
30 Yang SY, Nguyen TT, Ung TT, Jung YD. Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression. Chonnam Med J 2017;53:178-86. [PMID: 29026705 DOI: 10.4068/cmj.2017.53.3.178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Hu J, Li J, Yue X, Wang JC, Wang JF, Liu JZ, Kong DL. Targeting BCRP/ABCG2 by RNA interference enhances the chemotherapy sensitivity of human colon cancer side population cells. J Huazhong Univ Sci Technolog Med Sci 2017;37:231-6. [PMID: 28397046 DOI: 10.1007/s11596-017-1720-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
32 Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014;5:2866-80. [PMID: 24930887 DOI: 10.18632/oncotarget.2003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
33 Morisaki T, Yashiro M, Kakehashi A, Inagaki A, Kinoshita H, Fukuoka T, Kasashima H, Masuda G, Sakurai K, Kubo N. Comparative proteomics analysis of gastric cancer stem cells. PLoS One. 2014;9:e110736. [PMID: 25379943 DOI: 10.1371/journal.pone.0110736] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
34 Stella GM, Gentile A, Balderacchi A, Meloni F, Milan M, Benvenuti S. Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. J Transl Med 2016;14:256. [PMID: 27590450 DOI: 10.1186/s12967-016-1008-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hu B, Zhang H, Wang Z, Zhang F, Wei H, Li L. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther 2017;18:974-83. [PMID: 29020498 DOI: 10.1080/15384047.2017.1385679] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 13.4] [Reference Citation Analysis]